B2BROKER
8.2.2024 09:28:35 CET | Business Wire | Press release
B2Broker, a global powerhouse of liquidity and technology in the B2B sector for crypto, Forex and financial sectors, has partnered with Tools for Brokers (TFB), which provides elite solutions to brokers, liquidity providers, prop trading agencies and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208106794/en/
B2Broker partners with Tools for Brokers to integrate Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides. (Graphic: Business Wire)
B2Broker aims to integrate TFB’s Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides.
Importance of B2Broker and TFB Partnership
This collaboration combines B2Broker’s robust liquidity services with TFB’s cutting-edge Trade Processor technology. Here’s what you can expect from the partnership:
Enhanced Risk Mitigation - Trade Processor liquidity gateway introduces the trade routing feature that significantly elevates risk management capabilities for B2Broker clients. The platform can also provide advanced trade routing solutions to retail brokers with their MT4/MT5 servers. Traders can also seamlessly switch between A-Book and B-Book, increasing their flexibility and ability to adapt to market trends.
Elevated Access - With this integration, B2Broker clients will seamlessly access MT4, MT5 and cTrader platforms. The external FIX API integration is also possible for connecting third-party platforms.
Intuitive UI and Advanced Analytics - the Trade Processor also streamlines the digital user interface, making it easy to obtain essential data and access B2Broker’s features. The trading History page now overviews closed positions and all relevant details. Additional pages allow clients to analyse open position stats and exposure metrics and monitor the server performance.
Arthur Azizov, CEO of B2Broker, shared his thoughts on the partnership: "Our collaboration with Tools for Brokers directly supports our goal to deliver innovative technology to clients. TFB's Trade Processor upgrades our offerings with improved risk management and seamless integration across major trading platforms. At the same time, this partnership opens up B2Broker's extensive liquidity pool of over 800 pairs across eight asset classes to TFB users. It’s a mutual exchange of strengths that promises to enhance the value we, B2Broker and TFB, aim to deliver to our clients."
Alexey Kutsenko, the CEO at Tools for Brokers, outlined his excitement for the upcoming collaboration: “We are excited to partner with B2Broker. The company is well-known for its powerful ecosystem of products for brokers. I am confident that together we will create an even stronger solution for B2Brokers’ clients and help them grow faster and stay resilient.”
About Tools for Brokers
Tools for Brokers (TFB) is a global tech provider that serves retail brokers, LPs, prop trading firms and hedge funds operating on multiple platforms like MT4, MT5, Match-Trader and cTrader. TFB’s solutions are powered by their cutting-edge Trade Processor liquidity bridge. The core technology is further elevated by data analytics, risk mitigation tools, money management solutions and a single digital hub to manage TFB plugins effortlessly.
For more information, visit www.t4b.com
B2Broker’s Services
B2Broker is a global leader in the liquidity and fintech sector. B2Broker provides B2B services to forex brokers, crypto exchange platforms, prop traders, crypto spot brokers, multi-asset brokers and many other industries. B2Broker offers over 800 liquidity instruments supported by eight different asset classes. Moreover, the platform features payment processing solutions, white-label solutions, back-office, and numerous other mechanisms to create a full-stop liquidity and business management service for their B2B clients.
For more information, visit b2broker.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208106794/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom